APPLIED BIOCODE CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20 TWD | +1.27% |
|
+2.30% | -20.95% |
| Apr. 15 | Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use Only | CI |
| Mar. 21 | Applied BioCode Announces CEO Changes | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Capitalization 1 | 4,798 | 3,514 | 2,535 | 2,069 | 1,635 |
| Enterprise Value (EV) 1 | 4,798 | 3,514 | 2,535 | 2,069 | 1,635 |
| P/E ratio | -44.2 x | -21.3 x | -13.7 x | -12.6 x | -11.2 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 16 x | 11 x | 6.49 x | - | 3.8 x |
| EV / Revenue | 16 x | 11 x | 6.49 x | - | 3.8 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | -27.5 x | -21 x | 20.5 x | - | -11 x |
| FCF Yield | -3.63% | -4.76% | 4.88% | - | -9.11% |
| Price to Book | - | 3.89 x | 3.11 x | - | 2.5 x |
| Nbr of stocks (in thousands) | 81,593 | 81,729 | 81,763 | 81,768 | 81,768 |
| Reference price 2 | 58.80 | 43.00 | 31.00 | 25.30 | 20.00 |
| Announcement Date | 3/28/21 | 3/28/22 | 3/22/23 | 3/14/24 | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net sales 1 | 299 | 320 | 390.3 | - | 430 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -133.5 | -164.9 | -192.6 | - | -169 |
| Operating Margin | -44.65% | -51.55% | -49.35% | - | -39.3% |
| Earnings before Tax (EBT) 1 | -103.5 | -165.2 | -184.7 | - | -145 |
| Net income 1 | -103.5 | -165.2 | -184.7 | -164.2 | -145 |
| Net margin | -34.61% | -51.63% | -47.33% | - | -33.72% |
| EPS 2 | -1.330 | -2.020 | -2.260 | -2.010 | -1.780 |
| Free Cash Flow 1 | -174.3 | -167.3 | 123.7 | - | -149 |
| FCF margin | -58.3% | -52.28% | 31.7% | - | -34.65% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/28/21 | 3/28/22 | 3/22/23 | 3/14/24 | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q3 | 2022 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 109.5 | - | 120.7 | 90 | 92 | 112 | 136 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -23.55 | - | -39.36 | -43 | -51 | -42 | -34 |
| Operating Margin | - | -21.5% | - | -32.6% | -47.78% | -55.43% | -37.5% | -25% |
| Earnings before Tax (EBT) 1 | - | -25.45 | - | -35.21 | -37 | -45 | -36 | -28 |
| Net income 1 | -61.1 | -25.47 | -44.11 | -35.21 | -37 | -45 | -36 | -28 |
| Net margin | - | -23.26% | - | -29.16% | -41.11% | -48.91% | -32.14% | -20.59% |
| EPS 2 | -0.7500 | -0.3100 | -0.5400 | -0.4300 | -0.4500 | -0.5500 | -0.4400 | -0.3400 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 3/28/22 | 11/11/22 | 3/22/23 | - | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | -174 | -167 | 124 | - | -149 |
| ROE (net income / shareholders' equity) | -12.8% | -16.6% | -21.5% | - | -24.7% |
| ROA (Net income/ Total Assets) | -10.6% | -14.7% | -16.6% | - | -17.6% |
| Assets 1 | 973.1 | 1,123 | 1,116 | - | 823.4 |
| Book Value Per Share 2 | - | 11.10 | 9.980 | - | 8.000 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | 27.6 | 15.5 | 22.1 | - | - |
| Capex / Sales | 9.22% | 4.85% | 5.67% | - | - |
| Announcement Date | 3/28/21 | 3/28/22 | 3/22/23 | 3/14/24 | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
20
TWD
Average target price
22
TWD
Spread / Average Target
+10.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.95% | 50.02M | |
| -14.31% | 11.41B | |
| +70.85% | 3.81B | |
| -29.35% | 2.3B | |
| -12.90% | 2.16B | |
| +37.48% | 1.19B | |
| -2.40% | 760M | |
| -15.17% | 506M | |
| -34.29% | 444M | |
| +13.72% | 339M |
- Stock Market
- Equities
- 6598 Stock
- Financials Applied BioCode Corporation